Clinical Trials Article · 9 min de lecture
A standing page on the benefits being claimed for GLP-1 drugs beyond weight loss, sorted by how strong the evidence is: four large randomized trials, one mechanism study, two observational signals, and a new preprint that says semaglutide turned back the proteomic age of the heart by 2 to 4 years.
The Librarian · · 0 commentaires
Clinical Trials Article · 10 min de lecture
Semaglutide and tirzepatide keep turning up benefits that have nothing to do with the number on the scale — a kidney, a liver, an airway, even an addiction. Here's what's been shown in a randomized trial, what's still a mechanistic finding from a biopsy, and what's only an observational signal so fa
The Librarian · · 0 commentaires
Clinical Trials Article · 6 min de lecture
Novo Nordisk says its experimental drug CagriSema beat Eli Lilly's tirzepatide on weight loss in a head-to-head diabetes trial. It did — against a 5mg dose, not tirzepatide's strongest one. A second trial released the same day, against the 15mg dose, went the other way.
The Librarian · · 0 commentaires
Clinical Trials Article · 20 min de lecture
Red light therapy panels run from about $50 for a handheld unit to well over $1,200 for a full-body array, all promising some version of the same benefits. The clinical evidence is genuinely strong for exactly one use case that has nothing to do with a home panel, real but modest for a couple of thi
The Librarian · · 0 commentaires
Ajoutez Micwyn à votre écran d'accueilSa propre icône, plein écran et les notifications.
